News/ News/ News/ Patients/ R&D Ligelizumab could top Xolair in chronic hives, says Novartis Phil Taylor dermatology, hives, immunology, Novartis, Roche, Xolair 0 Comment Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share X Ligelizumab could top Xolair in chronic hives, says Novartis https://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
News/ News/ R&D Novartis takes Xolair follow-up into phase III hives trial Phil Taylor hives, Novartis, Xolair 0 Comment Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, Share X Novartis takes Xolair follow-up into phase III hives trial https://pharmaphorum.com/news/novartis-takes-xolair-follow-up-into-phase-iii-hives-trial/
dermatology, hives, immunology, Novartis, Roche, Xolair
0 Comment
